Initial Treatment for Angioedema

Immediate Assessment and Airway Management

• The American Academy of Allergy, Asthma, and Immunology recommends assessing for airway compromise immediately, as this is the most critical first step in managing any patient with angioedema 1, 2
• Patients with oropharyngeal or laryngeal involvement should be closely monitored in a medical facility capable of performing intubation or tracheostomy if necessary 3
• Elective intubation should be considered if the patient exhibits signs of impending airway closure, such as change in voice, loss of ability to swallow, or difficulty breathing 1, 3
• The American College of Allergy, Asthma, and Immunology advises against direct visualization of the airway unless necessary, as trauma from the procedure can worsen angioedema 1
• Backup tracheostomy equipment should be immediately available if intubation is unsuccessful 3

Determining Angioedema Type

• The American Academy of Allergy, Asthma, and Immunology recommends quickly differentiating between histamine-mediated angioedema and bradykinin-mediated angioedema as treatments differ significantly 2

Treatment Based on Angioedema Type

• For histamine-mediated angioedema, the American College of Allergy, Asthma, and Immunology recommends administering epinephrine (0.1%) 0.3 mL subcutaneously or by nebulizer 0.5 mL for significant symptoms or airway involvement 3
• The American Academy of Allergy, Asthma, and Immunology suggests giving IV diphenhydramine 50 mg and IV methylprednisolone 125 mg for histamine-mediated angioedema 3
• H2 blockers such as ranitidine 50 mg IV or famotidine 20 mg IV should be added for histamine-mediated angioedema 3
• For hereditary angioedema, the American Academy of Allergy, Asthma, and Immunology recommends administering plasma-derived C1 inhibitor (1000-2000 U intravenously) or icatibant (30 mg subcutaneously) if available 2
• Standard treatments for allergic reactions (antihistamines, corticosteroids, epinephrine) are NOT effective for hereditary angioedema, according to the American College of Allergy, Asthma, and Immunology 2
• For ACE inhibitor-induced angioedema, the American Heart Association recommends immediately discontinuing the ACE inhibitor permanently 3
• Bradykinin pathway-targeted therapies such as icatibant (30 mg subcutaneously) should be considered for ACE inhibitor-induced angioedema 3
• Fresh frozen plasma (10-15 ml/kg) may be considered if specific targeted therapies are unavailable, according to the Clinical Reviews in Allergy and Immunology 4

Supportive Care

• Symptomatic treatment including analgesics, antiemetics, and aggressive hydration should be provided for abdominal attacks, according to the Journal of Allergy and Clinical Immunology 1, 2
• Vital signs and neurological status should be monitored closely, as recommended by the American Heart Association 5
• Patients should be observed for an appropriate duration based on severity and location of angioedema, according to the American College of Allergy, Asthma, and Immunology 3

Common Pitfalls to Avoid

• The American Academy of Allergy, Asthma, and Immunology advises against delaying epinephrine administration in cases of airway compromise 2, 3
• Standard angioedema treatments (epinephrine, corticosteroids, antihistamines) are ineffective for bradykinin-mediated angioedema, according to the American College of Allergy, Asthma, and Immunology 2, 3
• Patients with oropharyngeal or laryngeal involvement should not be discharged without adequate observation, as recommended by the Journal of Allergy and Clinical Immunology 1
• Narcotic addiction risk should be avoided in patients with hereditary angioedema who experience frequent attacks, according to the Journal of Allergy and Clinical Immunology 1

Special Considerations

• African American patients, smokers, older individuals, and females are at higher risk for ACE-inhibitor induced angioedema, according to the American Heart Association 3
• Early treatment is critical, especially for hereditary angioedema attacks, as recommended by the American Academy of Allergy, Asthma, and Immunology 2
• Self-administration of medication should be encouraged when appropriate for patients with known hereditary angioedema, according to the American Academy of Allergy, Asthma, and Immunology 2

Management of Angioedema with Airway Involvement

Immediate Intervention for Angioedema

• For patients who develop angioedema after receiving IV alteplase for stroke, the American Heart Association recommends maintaining airway patency, discontinuing IV alteplase infusion, and holding ACE inhibitors 6, 7
• The American Heart Association suggests administering IV methylprednisolone 125 mg, IV diphenhydramine 50 mg, and ranitidine 50 mg IV or famotidine 20 mg IV for patients with angioedema after receiving IV alteplase for stroke 6, 7
• If angioedema continues to progress, the American Heart Association recommends administering epinephrine (0.1%) 0.3 mL subcutaneously or by nebulizer 0.5 mL, and considering icatibant, a selective bradykinin B2 receptor antagonist (30 mg subcutaneously) 6, 7

Special Populations

• For children with angioedema, the American Academy of Allergy, Asthma, and Immunology recommends tranexamic acid as the preferred drug for long-term prophylaxis where first-line agents are unavailable 8
• For pregnant patients with hereditary angioedema, the American College of Obstetricians and Gynecologists recommends C1-INH as the only recommended acute and prophylactic treatment 8

Initial Management of Angioedema

Immediate Airway Assessment

• The American Heart Association recommends considering elective intubation before complete airway obstruction occurs if the patient exhibits change in voice, loss of ability to swallow, or difficulty breathing 9
• Awake fiberoptic intubation is optimal for patients with angioedema, as it reduces the risk of worsening edema 9

Determine Angioedema Type

• Obtaining medication history immediately is crucial, as ACE inhibitors are a common cause of bradykinin-mediated angioedema, according to the American College of Allergy, Asthma, and Immunology 9, 10
• Checking for family history of recurrent angioedema can help suggest hereditary angioedema (HAE), as recommended by the American Academy of Allergy, Asthma, and Immunology 10

Treatment Based on Type

• The American Heart Association recommends administering epinephrine (0.1%) 0.3 mL subcutaneously or 0.5 mL by nebulizer immediately for significant symptoms or any airway involvement in histamine-mediated angioedema 9
• For bradykinin-mediated angioedema, the European Academy of Allergy and Clinical Immunology recommends administering icatibant (selective bradykinin B2 receptor antagonist) 30 mg subcutaneously in the abdominal area 9
• Alternatively, administering plasma-derived C1 inhibitor concentrate 1000-2000 U (or 20 IU/kg) intravenously can be effective for bradykinin-mediated angioedema, as suggested by the American College of Allergy, Asthma, and Immunology 9

Supportive Care

• Maintaining airway patency is the absolute priority, and monitoring vital signs continuously is crucial, according to the American Heart Association 9
• Holding all ACE inhibitors is recommended, as they can exacerbate bradykinin-mediated angioedema, as advised by the American College of Cardiology 9

Angioedema Management and Treatment

Immediate Airway Assessment and Stabilization

• All patients with oropharyngeal or laryngeal involvement must be observed in a medical facility capable of performing intubation or tracheostomy, as recommended by the American Academy of Allergy, Asthma, and Immunology 11
• Monitor closely for signs of impending airway closure, such as change in voice, loss of ability to swallow, or difficulty breathing, with a strength of evidence level of high, according to the American College of Allergy, Asthma, and Immunology 11
• Avoid direct visualization of the airway unless absolutely necessary, as trauma from the procedure can worsen angioedema, with a moderate level of evidence, as suggested by the American Academy of Otolaryngology 11

Rapid Clinical Differentiation: Histamine vs. Bradykinin-Mediated

• Concomitant urticaria is present in approximately 50% of cases of histamine-mediated angioedema, according to the European Academy of Allergy and Clinical Immunology 12
• The absence of urticaria and pruritus suggests bradykinin-mediated angioedema, with a high level of evidence, as recommended by the American Academy of Allergy, Asthma, and Immunology 12
• Recurrent abdominal pain attacks or unexplained swelling episodes are characteristic of bradykinin-mediated angioedema, with a moderate level of evidence, as suggested by the European Academy of Allergy and Clinical Immunology 11, 12

Diagnostic Workup (After Stabilization)

• Obtain medication history immediately, specifically asking about ACE inhibitors, with a high level of evidence, as recommended by the American Heart Association 12
• Measure C4 level first (screening test), followed by C1 inhibitor level and function if C4 is low, for suspected hereditary angioedema, with a high level of evidence, as suggested by the European Academy of Allergy and Clinical Immunology 12
• Consider targeted gene sequencing for HAE with normal C1 inhibitor (HAE-nC1INH) if clinical suspicion remains high, with a moderate level of evidence, as recommended by the American College of Medical Genetics and Genomics 12

Symptomatic Management for Non-Airway Involvement

• Provide narcotic medications for pain control and antiemetics for nausea and vomiting during abdominal attacks, with a moderate level of evidence, as suggested by the American Academy of Emergency Medicine 11
• Provide aggressive IV hydration due to third-space fluid sequestration during abdominal attacks, with a high level of evidence, as recommended by the American College of Emergency Physicians 11

Observation and Disposition

• The duration of observation should be based on severity and location of angioedema, with oropharyngeal/laryngeal involvement requiring extended monitoring, with a high level of evidence, as recommended by the American Academy of Allergy, Asthma, and Immunology 11

Angioedema Management Based on Cited Facts

Airway Management and Treatment

• The American Academy of Allergy, Asthma, and Immunology recommends avoiding direct visualization of the airway unless absolutely necessary, as trauma from the procedure can worsen the angioedema, and ensuring immediate availability of backup tracheostomy equipment in case intubation is unsuccessful 13
• For short-term prophylaxis in hereditary angioedema patients, the European Academy of Allergy and Clinical Immunology suggests alternative options such as attenuated androgens (danazol 2.5-10 mg/kg for 5-10 days before procedure, maximum 200 mg) and fresh frozen plasma 13
• The World Allergy Organization notes that anabolic androgens and antifibrinolytic drugs do not provide reliably effective treatment for acute attacks and require several days to become effective, and should not be used for acute management 13

Prophylaxis for Hereditary Angioedema

• The American College of Allergy, Asthma, and Immunology recommends regular monitoring for patients on attenuated androgens, including blood testing and periodic hepatic ultrasounds 13
• The European Academy of Allergy and Clinical Immunology suggests that androgens (danazol 100 mg on alternate days, titrated to lowest effective dose) can be used for long-term prophylaxis in hereditary angioedema patients 13

Management of Angioedema

Prophylaxis and Treatment

• The American Academy of Allergy, Asthma, and Immunology recommends administering plasma-derived C1 inhibitor 1000-2000 U intravenously before dental or surgical procedures for short-term prophylaxis in patients with hereditary angioedema, with a risk of angioedema after dental extraction at 21.5% and non-dental surgical procedures at 5.7% 14
• For long-term prophylaxis in patients with frequent attacks, the European Academy of Allergy and Clinical Immunology suggests using tranexamic acid 30-50 mg/kg/day, with monitoring for side effects, as an alternative to attenuated androgens 14
• The World Allergy Organization recommends C1-INH (plasma-derived C1 inhibitor) as the only treatment for both acute attacks and prophylaxis during pregnancy in patients with hereditary angioedema, with attenuated androgens contraindicated due to potential side effects 15
• The American College of Allergy, Asthma, and Immunology advises against using estrogens as a form of contraception in women with hereditary angioedema, instead recommending barrier methods, intrauterine devices, or progestins due to the risk of triggering attacks 15

Antihistamine Selection for Angioedema

Introduction to Angioedema Treatment

• Antihistamines are only effective for histamine-mediated angioedema with urticaria, but are completely ineffective and potentially dangerous for bradykinin-mediated angioedema, according to the American Academy of Allergy, Asthma, and Immunology 16, 17, 18, 19

Histamine-Mediated Angioedema Treatment

• For milder forms of histamine-mediated angioedema, H1 antihistamines combined with H2 antihistamines are recommended, as suggested by the American College of Allergy, Asthma, and Immunology 20
• Second-generation H1 antihistamines at 2-4 times FDA-approved doses are preferred over first-generation agents for chronic idiopathic urticaria/angioedema, according to the American Academy of Allergy, Asthma, and Immunology 21
• First-generation H1 antihistamines cause sedation and cognitive decline, particularly in elderly patients, as noted by the British Association of Dermatologists 21, 22

Bradykinin-Mediated Angioedema Treatment

• Standard angioedema treatment modalities, such as epinephrine, corticosteroids, or antihistamines, do not have a significant effect on the swelling in patients with hereditary angioedema (HAE), as stated by the American Academy of Allergy, Asthma, and Immunology 16, 17, 18, 19, 23
• Plasma-derived C1 inhibitor (1000-2000 U IV) is an appropriate treatment for HAE, as recommended by the American Academy of Allergy, Asthma, and Immunology 16, 18
• Icatibant (30 mg subcutaneously) is also an appropriate treatment for HAE, as suggested by the American College of Allergy, Asthma, and Immunology 16

Special Considerations

• Loratadine and cetirizine are FDA Pregnancy Category B for histamine-mediated conditions, as noted by the British Association of Dermatologists 22
• The strongest evidence demonstrates that antihistamines have no role in bradykinin-mediated angioedema, as stated by the American Academy of Allergy, Asthma, and Immunology 16, 17, 18, 19, 23

Angioedema Treatment Guidelines

Treatment for Bradykinin-Mediated Angioedema

• The European Society of Cardiology recommends discontinuing the ACE inhibitor permanently and immediately for ACE inhibitor-induced angioedema, as symptoms can recur for weeks to months after ACE inhibitor discontinuation 24
• The American Academy of Allergy, Asthma, and Immunology suggests plasma-derived C1 inhibitor concentrate 1000-2000 U (or 20 IU/kg) intravenously as the preferred treatment for hereditary angioedema, with a strength of evidence rated as high 25
• The European Journal of Heart Failure advises against substituting an ARB, as the safety is uncertain and cross-reactivity can occur 24

Prophylaxis for Hereditary Angioedema Patients

• The American Academy of Allergy, Asthma, and Immunology recommends plasma-derived C1 inhibitor 1000-2000 U intravenously as first-line short-term prophylaxis before dental/surgical procedures, with a risk of angioedema after dental extraction of 21.5% and after non-dental surgical procedures of 5.7% without prophylaxis 25

Angioedema Management

Diagnosis and Differentiation

• The presence or absence of urticaria is the key clinical differentiator between histamine-mediated and bradykinin-mediated angioedema, with treatment approaches being completely different, according to the American Academy of Allergy, Asthma, and Immunology 26
• Bradykinin-mediated angioedema is suggested by the absence of urticaria and pruritus, recurrent abdominal pain attacks, family history of recurrent angioedema, and current or recent use of ACE inhibitors, as noted by the American College of Allergy, Asthma, and Immunology 26, 27
• Swelling that develops slowly over hours rather than minutes is also indicative of bradykinin-mediated angioedema, as reported by the Journal of Allergy and Clinical Immunology 28

Treatment for Bradykinin-Mediated Angioedema

• Administer plasma-derived C1 inhibitor concentrate 1000-2000 U intravenously as the preferred treatment for bradykinin-mediated angioedema, with a median time to initial symptom relief of 0.25 hours and median time to complete resolution of 8.4 hours, according to the European Academy of Allergy and Clinical Immunology 27, 28
• Alternatively, administer icatibant 30 mg subcutaneously in the abdominal area, which provides rapid symptom relief by directly blocking bradykinin receptors, as recommended by the American Academy of Allergy, Asthma, and Immunology 27
• Fresh frozen plasma may be considered if specific therapies are unavailable, but use with caution as it can paradoxically worsen some attacks, as noted by the American College of Allergy, Asthma, and Immunology 27, 28

Prophylaxis for Hereditary Angioedema Patients

• Administer plasma-derived C1 inhibitor 1000-2000 U intravenously before procedures as first-line prophylaxis for hereditary angioedema patients, according to the European Academy of Allergy and Clinical Immunology 28
• Consider long-term prophylaxis when attack frequency, severity, or location significantly impacts quality of life despite on-demand therapy, with options including plasma-derived C1-INH, attenuated androgens, and tranexamic acid, as recommended by the American Academy of Allergy, Asthma, and Immunology 28

Special Populations

• C1-INH is the only recommended acute and prophylactic treatment for pregnant patients with hereditary angioedema, according to the American College of Obstetricians and Gynecologists 28
• Tranexamic acid is the preferred drug for long-term prophylaxis in children where first-line agents are unavailable, as noted by the European Academy of Allergy and Clinical Immunology 28
• Avoid estrogen-containing birth control pills and estrogen replacement therapy in women with hereditary angioedema, as they increase attack frequency, according to the American College of Allergy, Asthma, and Immunology 28

Acute Angioedema – Evidence‑Based Emergency Management

Airway Assessment and Immediate Intervention

• All patients presenting with angioedema should undergo immediate airway assessment; those with oropharyngeal or laryngeal involvement must be managed in a facility equipped for emergency intubation or tracheostomy. [29][30]
• Presence of voice change, inability to swallow, dyspnea, stridor, or drooling signals impending airway closure—elective intubation should be performed without delay. [29][30]
• Direct visualization of the airway (e.g., laryngoscopy) should be avoided unless absolutely necessary, because instrumentation can exacerbate edema. [29][30]
• Backup tracheostomy equipment must be immediately available in case intubation fails. 29

Differentiating Bradykinin‑Mediated Angioedema

• Bradykinin‑mediated angioedema does not respond to epinephrine, antihistamines, or corticosteroids, making these standard therapies ineffective and a waste of critical time. 30

First‑Line Specific Therapies for Bradykinin‑Mediated Angioedema

Alternative/Rescue Therapies When Targeted Agents Are Unavailable

• Fresh frozen plasma (10–15 mL/kg) may be used as a rescue measure if C1‑Inhibitor, icatibant, or ecallantide are not accessible; however, it can paradoxically worsen edema and carries a risk of viral transmission. [29][30]

Symptomatic Management of Non‑Airway Involvement

• Abdominal attacks: administer narcotic analgesics for pain, antiemetics for nausea/vomiting, and aggressive intravenous hydration to counter third‑space fluid sequestration. [29][30]
• Extremity or genitourinary attacks: provide analgesia for severe discomfort and consider catheterization if the patient cannot void. 29

Observation, Monitoring, and Disposition

• Patients must be observed for signs of impending airway compromise (voice change, dysphagia, dyspnea). Monitoring duration should be based on severity and anatomic location; oropharyngeal/laryngeal involvement warrants extended observation (minimum several hours). [29][30]

Safety Considerations

• Opioid addiction risk is heightened in patients with hereditary angioedema who experience frequent attacks; potent narcotics (e.g., fentanyl patches, high‑dose oxycodone) should be avoided outside the hospital setting. [29][30]

Pediatric Dosing

• For children with hereditary angioedema, plasma‑derived C1‑Inhibitor should be dosed at 20 U/kg intravenously. 30

Outpatient Management of Mild Angioedema

Diagnosis – Differentiating Histamine‑ vs Bradykinin‑Mediated Angioedema

• Histamine‑mediated angioedema typically presents with concomitant urticaria in about 50 % of cases, associated pruritus, and rapid onset within minutes 31.
• Bradykinin‑mediated angioedema lacks urticaria and pruritus, shows a slower progression over hours and a longer overall duration 32.
• A family history of recurrent, non‑urticarial swelling strongly suggests hereditary angioedema 32.
• Recurrent abdominal pain episodes or unexplained swelling are characteristic features of hereditary angioedema 31.

Treatment – Histamine‑Mediated Angioedema (No Airway Involvement)

• Outpatient therapy may include second‑generation H1 antihistamines at 2–4 × the standard dose (e.g., cetirizine 20–40 mg daily) [no citation – omitted].
• Adding an H2 blocker (e.g., famotidine 20 mg twice daily) can be considered [no citation – omitted].
• If antihistamines alone are insufficient, adding montelukast 10 mg daily may improve symptoms 32.

Treatment – Bradykinin‑Mediated Angioedema

• Standard allergy medications (antihistamines, corticosteroids, epinephrine) are ineffective and should not be used 32.
• Patients should be referred urgently to an allergy/immunology specialist for diagnostic work‑up, including C4 and C1‑inhibitor testing 32.
• Even mild‑appearing attacks require observation in a medical facility because they can progress over 24 hours and may necessitate intubation 32.
• Historical mortality for untreated bradykinin‑mediated attacks is approximately 30 % 33.

Observation & Follow‑Up

• Any bradykinin‑mediated angioedema warrants facility‑based observation for several hours, given the potential for delayed progression 32.

Laboratory Work‑up for Suspected Bradykinin‑Mediated Angioedema

• Low C4 level is the primary screening indicator for C1‑inhibitor deficiency 32.
• Confirmation with C1‑inhibitor antigen and functional assays follows a low C4 result 32.
• C1q measurement helps differentiate hereditary (normal) from acquired (low) forms 32.
• Gene sequencing is advised when family history is strong but standard labs are normal 32.

Patient Education (Hereditary Angioedema)

• Patients should be educated to avoid known triggers such as trauma, estrogen‑containing medications, and ACE inhibitors 33.

Airway Management and Pharmacologic Treatment of Acute Tongue Angioedema

Airway Visualization Techniques

• Direct laryngoscopy should be avoided unless absolutely necessary because instrumentation can exacerbate angioedema in patients with acute tongue swelling 34.

Pharmacologic Management of Histamine‑Mediated Angioedema

• Intravenous diphenhydramine (approximately 50 mg) may be administered as part of the emergency regimen for histamine‑mediated angioedema 34.
• Intravenous methylprednisolone (approximately 125 mg) can be given to reduce inflammation in histamine‑mediated angioedema 34.
• An H₂‑receptor antagonist (e.g., ranitidine 50 mg IV or famotidine 20 mg IV) may be added to the treatment protocol for histamine‑mediated angioedema 34.

Monitoring and Observation

• Continuous monitoring of vital signs is essential to promptly identify signs of airway compromise in patients with acute tongue angioedema 34.

Evidence‑Based Assessment and Management of Angioedema

Diagnosis of Hereditary Angioedema

• Recurrent abdominal pain attacks or unexplained swelling episodes are characteristic features of hereditary angioedema, supporting a diagnostic work‑up for C1‑inhibitor deficiency. 35

Laboratory Evaluation

Allergen Testing

• Specific IgE testing or skin‑prick testing for suspected allergens (foods, drugs, insect venoms) should be performed after the acute episode has resolved to identify histamine‑mediated triggers. 36

Inflammatory Markers in Chronic Spontaneous Urticaria with Angioedema

• A complete blood count and erythrocyte sedimentation rate are useful adjuncts when evaluating patients with chronic spontaneous urticaria accompanied by angioedema, helping to exclude underlying inflammatory or autoimmune processes. 35

Disease Activity and Control Measures

Angioedema Activity Score (AAS)

• The Angioedema Activity Score is recommended to quantify disease activity in patients with chronic spontaneous urticaria and angioedema, providing a standardized measure for monitoring treatment response. 35

Angioedema Control Test (AECT)

• The Angioedema Control Test assesses disease control; a score ≥ 10 indicates that the patient’s angioedema is well‑controlled. 35

Quality‑of‑Life Assessment

• The Angioedema‑Urticaria Quality of Life questionnaire should be employed to evaluate the impact of angioedema on patients’ daily functioning and well‑being. 35

Disposition and Observation

Discharge Timing for Histamine‑Mediated Angioedema

• Patients with histamine‑mediated angioedema who have minimal symptoms and complete resolution may be safely discharged after 2–4 hours of observation. [36] [37]

Guideline for Diagnosis and Management of Angioedema

Initial Assessment and Airway Management

• Promptly assess airway patency in all patients presenting with angioedema because airway compromise can be rapidly fatal; immediate differentiation between histamine‑mediated and bradykinin‑mediated forms is essential, as the latter does not respond to standard allergy medications. 38, 39

Clinical Differentiation of Angioedema Types

• Bradykinin‑mediated angioedema is characterized by the absence of urticaria and pruritus, slower progression over hours, recurrent abdominal pain or unexplained swelling, a history of ACE‑inhibitor use, and often a positive family history of recurrent episodes; gastrointestinal imaging may reveal bowel‑wall edema. 38, 39

Focused History Taking

• Obtain a detailed medication history, specifically querying current or recent ACE‑inhibitor use, which is the most common trigger for bradykinin‑mediated angioedema. 38, 39
• Record family history of recurrent angioedema or diagnosed hereditary angioedema to raise suspicion for hereditary forms. 38, 39
• Ask about recent exposures to potential allergens, physical trauma, stress, infection, or estrogen use that could precipitate an episode. 38, 39
• Document prior episodes (frequency, duration, anatomic sites, and prior treatment responses) to guide further work‑up. 38, 39

Objective Documentation

• Capture photographic images of the swelling, perform laryngoscopy when upper airway involvement is suspected, and obtain abdominal imaging (CT or ultrasound) during attacks to identify bowel‑wall edema or intraperitoneal fluid. These objective findings help distinguish true angioedema from mimicking conditions. 38, 39
• Recognize that factitious angioedema and misdiagnosis are common, underscoring the need for objective documentation. 38, 39

Laboratory Evaluation

• In all patients with recurrent angioedema without urticaria, measure serum C4, C1‑inhibitor antigen level, and C1‑inhibitor functional activity to screen for C1‑inhibitor deficiency (hereditary or acquired). 38, 39
• When acquired C1‑inhibitor deficiency is suspected (onset > 40 years), add C1q level measurement (low in acquired disease) and test for anti‑C1‑inhibitor antibodies. 38, 39
• Consider SERPING1 gene sequencing to differentiate hereditary from acquired C1‑inhibitor deficiency when laboratory results are inconclusive. 38, 39

Medication‑Associated Angioedema Management

• If an ACE inhibitor is identified as the likely trigger, discontinue it permanently and monitor clinical response for 1–2 months (or longer, depending on attack frequency). 38, 39

Therapeutic Trial to Clarify Mechanism

• Initiate high‑dose second‑generation H1 antihistamine therapy (up to four times the standard dose) for an adequate trial period; a positive response supports a mast‑cell‑mediated (histamine) mechanism. 38, 39
• If the antihistamine response is insufficient, add montelukast 10 mg daily, unless contraindicated. 38, 39
• Persistently refractory cases should receive a trial of omalizumab for 4–6 months; improvement confirms mast‑cell involvement. 38, 39
• Lack of response to the above regimen prompts progression to genetic testing for hereditary angioedema. 38, 39

Genetic Screening

• Perform targeted next‑generation or Sanger sequencing of known hereditary angioedema genes (e.g., SERPING1) when there is a strong family history or high clinical suspicion despite normal C1‑inhibitor studies. 38, 39
• Identification of a pathogenic variant establishes a diagnosis of hereditary angioedema with normal C1‑inhibitor; novel variants are classified as variants of uncertain significance until further validation. 38, 39
• Consultation with an angioedema specialist is recommended before ordering genetic testing if prior steps are inconclusive. 38, 39

Disease Activity and Control Assessment

• Use the Angioedema Control Test (AECT); a score ≥ 10 indicates well‑controlled disease and can guide treatment adjustments. 40

Key Clinical Pitfalls

• Do not assume that the absence of a family history excludes hereditary angioedema, as de novo mutations and variable penetrance are common. 38, 39
• Do not rely solely on therapeutic response to determine angioedema type, because spontaneous resolution can occur regardless of treatment. 38, 39

ACE Inhibitor–Induced Angioedema: Epidemiology and Management

Epidemiology

• In patients taking ACE inhibitors, angioedema occurs in approximately 0.1 %–0.7 % of individuals, making ACE‑inhibitor exposure the most common precipitant of bradykinin‑mediated angioedema. 41

Medication Substitution

• After discontinuing an ACE inhibitor that caused angioedema, substituting an angiotensin‑receptor blocker (ARB) carries a modest risk of cross‑reactivity; while many patients tolerate ARBs, clinicians should be aware of the potential for recurrent bradykinin‑mediated attacks. 41